Background Cervical cancer is the most common cancer among women in Botswana and elsewhere in Sub-Saharan Africa. We sought to examine whether HPV vaccine is acceptable among parents in Botswana, which recently licensed the vaccine to prevent cervical cancer. Methods and Findings We conducted a cross-sectional survey in 2009, around the time the vaccine was first licensed, with adults recruited in general medicine and HIV clinics in Gaborone, the capital of Botswana. Although only 9% (32/376) of respondents had heard of HPV vaccine prior to the survey, 88% (329/376) said they definitely will have their adolescent daughters receive HPV vaccine. Most respondents would get the vaccine for their daughters at a public or community clinic (42%) or a gynecology or obstetrician's office (39%), and 74% would get it for a daughter if it were available at her school. Respondents were more likely to say that they definitely will get HPV vaccine for their daughters if they had less education (OR = 0.20, 95% CI = 0.07–0.58) or lived more than 30 kilometers from the capital, Gaborone (OR = 2.29, 95% CI = 1.06–4.93). Other correlates of acceptability were expecting to be involved in the decision to get HPV vaccine, thinking the vaccine would be hard to obtain, and perceiving greater severity of HPV-related diseases. Conclusions HPV vaccination of adolescent girls would be highly acceptable if the vaccine became widely available to the daughters of healthcare seeking parents in Gaborone, Botswana. Potential HPV vaccination campaigns should provide more information about HPV and the vaccine as well as work to minimize barriers.
References
[1]
World Health Organization (WHO).HPV and related cancers for africa. (2010 November 14).
[2]
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2008) 2008 report on the global AIDS epidemic. (2010 November 14).
[3]
Wright TC Jr, Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW (1994) Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of papanicolaou smears. new york cervical disease study. Obstet Gynecol 84(4): 591–597.
[4]
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, et al. (2007) Quadrivalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 56(RR-2): 1–24.
[5]
Brewer NT, Fazekas KI (2007) Predictors of HPV vaccine acceptability: A theory-informed, systematic review. Prev Med 45(2–3): 107–114. 10.1016/j.ypmed.2007.05.013.
Winkler JL, Wittet S, Bartolini RM, Creed-Kanashiro HM, Lazcano-Ponce E, et al. (2008) Determinants of human papillomavirus vaccine acceptability in latin america and the caribbean. Vaccine 26: Suppl 11L73–9. 10.1016/j.vaccine.2008.05.027.
[8]
Breitkopf CR, Pearson HC, Dinh TA, Tran BC, Vu T, et al. (2009) Human papillomavirus vaccine decision-making in da nang, vietnam: Perceived spousal and adolescent-parent concordance. Vaccine 27(17): 2367–2371. 10.1016/j.vaccine.2009.02.021.
[9]
Sam IC, Wong LP, Rampal S, Leong YH, Pang CF, et al. (2009) Maternal acceptance of human papillomavirus vaccine in malaysia. J Adolesc Health 44(6): 610–612. 10.1016/j.jadohealth.2008.11.014.
[10]
Li J, Li LK, Ma JF, Wei LH, Niyazi M, et al. (2009) Knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines among women living in metropolitan and rural regions of china. Vaccine 27(8): 1210–1215. 10.1016/j.vaccine.2008.12.020.
[11]
Madhivanan P, Krupp K, Yashodha MN, Marlow L, Klausner JD, et al. (2009) Attitudes toward HPV vaccination among parents of adolescent girls in mysore, india. Vaccine 27(38): 5203–5208. 10.1016/j.vaccine.2009.06.073.
[12]
Kwan TT, Chan KK, Yip AM, Tam KF, Cheung AN, et al. (2008) Barriers and facilitators to human papillomavirus vaccination among chinese adolescent girls in hong kong: A qualitative-quantitative study. Sex Transm Infect 84(3): 227–232. 10.1136/sti.2007.029363.
[13]
Harries J, Moodley J, Barone MA, Mall S, Sinanovic E (2009) Preparing for HPV vaccination in south africa: Key challenges and opinions. Vaccine 27(1): 38–44. 10.1016/j.vaccine.2008.10.033.
[14]
Katahoire RA, Jitta J, Kivumbi G, Murokora D, Arube WJ, et al. (2008) An assessment of the readiness for introduction of the HPV vaccine in uganda. Afr J Reprod Health 12(3): 159–172.
[15]
World Health Organization (WHO).HPV and related cancers for botswana. (2010 November 14).
[16]
United Nations Children's Fund (UNICEF).Botswana statistics. (2010 November 12).
[17]
McRee AL, Brewer NT, Reiter PL, Gottlieb SL, Smith JS (2009) The carolina HPV immunization attitudes and beliefs scale (CHIAS): Scale development and associations with intentions to vaccinate. Sex Transm Dis. . 10.1097/OLQ.0b013e3181c37e15.
[18]
Reiter PL, Brewer NT, Gottlieb SL, McRee AL, Smith JS (2009) Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med 69(3): 475–480. 10.1016/j.socscimed.2009.05.024.
[19]
Fazekas KI, Brewer NT, Smith JS (2008) HPV vaccine acceptability in a rural southern area. J Womens Health (Larchmt) 17(4): 539–548. 10.1089/jwh.2007.0489.
[20]
Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, et al. (2008) Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health 43: 4 SupplS61–7. 10.1016/j.jadohealth.2008.06.015.
[21]
Botswana Export Development and Investment Authority (BEDIA) (2008) Botswana statistics. 2010 November 15.
[22]
Black LL, Zimet GD, Short MB, Sturm L, Rosenthal SL (2009) Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine 27(11): 1668–1673. 10.1016/j.vaccine.2009.01.035.
[23]
Brewer NT, Gottlieb SL, Reiter PL, McRee AL, Liddon N, et al. (2011) Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis 38(3): 197–204. 10.1097/OLQ.0b013e3181f12dbf.
[24]
Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, et al. (2008) Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in manchester: Prospective cohort study. BMJ 336(7652): 1056–1058. 10.1136/bmj.39541.534109.BE.
[25]
Reeve C, De La Rue S, Pashen D, Culpan M, Cheffins T (2008) School-based vaccinations delivered by general practice in rural north queensland: An evaluation of a new human papilloma virus vaccination program. Commun Dis Intell 32(1): 94–98.
[26]
Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N (2009) Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 360(19): 1981–1988. 10.1056/NEJMsa0806477.
[27]
McFarland DM (2003) Cervical cancer and pap smear screening in botswana: Knowledge and perceptions. Int Nurs Rev 50(3): 167–175.
[28]
Agosti JM, Goldie SJ (2007) Introducing HPV vaccine in developing countries–key challenges and issues. N Engl J Med 356(19): 1908–1910. 10.1056/NEJMp078053.
